Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea

BACKGROUND: Delamanid, bedaquiline, and linezolid have recently been approved for the treatment of multidrug- and extensively drug-resistant (MDR and XDR, respectively) tuberculosis (TB). To use these drugs effectively, drug susceptibility tests, including rapid molecular techniques, are required fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jeong Seong, Kim, Kyung Jong, Choi, Hongjo, Lee, Seung Heon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society for Laboratory Medicine 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056398/
https://www.ncbi.nlm.nih.gov/pubmed/30027700
http://dx.doi.org/10.3343/alm.2018.38.6.563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056398/
https://www.ncbi.nlm.nih.gov/pubmed/30027700
http://dx.doi.org/10.3343/alm.2018.38.6.563

Ejemplares similares